Trex Wind Down Inc. (TMBRQ)
OTCMKTS: TMBRQ · Delayed Price · USD
0.0002
+0.0001 (100.00%)
May 3, 2024, 2:42 PM EDT - Market closed
Trex Wind Down Revenue
In the year 2022, Trex Wind Down had annual revenue of $83.18K, a decrease of -90.62%.
Revenue (ttm)
$83.18K
Revenue Growth
-90.62%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
616.22 USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 83.18K | -803.36K | -90.62% |
Dec 31, 2021 | 886.53K | 432.72K | 95.35% |
Dec 31, 2020 | 453.81K | - | - |
Jan 31, 2020 | 0 | - | - |
Jan 31, 2019 | 57.00K | -16.00K | -21.92% |
Jan 31, 2018 | 73.00K | -27.00K | -27.00% |
Jan 31, 2017 | 100.00K | 36.00K | 56.25% |
Jan 31, 2016 | 64.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.33B |
TMBRQ News
- 2 months ago - Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting - Business Wire
- 3 months ago - LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals - Business Wire
- 5 months ago - NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR) - Business Wire
- 5 months ago - Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American - GlobeNewsWire
- 5 months ago - NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR) - Business Wire
- 8 months ago - Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance - GlobeNewsWire
- 8 months ago - TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR - Business Wire
- 9 months ago - TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire